超性心肌病治疗的新型治疗途径
Dipti Patil1, Lokesh Kumar Bhatt2
1Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (West), Mumbai, 400056, India.
概括
增高性心肌病 (HCM) 是一种复杂的遗传性心脏病. 新的治疗目标正在出现,以解决对超越现有疗法 (如 mavacamten) 的新疗法的未满足需求.
科学领域:
- 心脏病学 心脏病学
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
背景情况:
- 增高性心肌病变 (HCM) 是一种异质遗传疾病,其特征是左心室增高,纤维化和扩张功能受损.
- 尽管了解HCM的分子机制取得了进展,但压力刺激和肌细胞生长之间的联系仍然不清楚.
- 目前的治疗选择有限,mavacamten是FDA批准的唯一药物,这突显了对新疗法的未满足需求.
研究的目的:
- 提供对超性心肌病 (HCM) 新兴治疗点的概述.
- 讨论新的分子途径和最近的发展,以在HCM治疗中潜在的临床应用.
主要方法:
- 综述当前关于缩性心肌病 (HCM) 病理生理学的文献.
- 基于新兴研究的新分子标的识别和讨论.
- 对针对特定分子通路的潜在治疗策略的分析.
主要成果:
- 已经确定了几种新的分子标,用于HCM治疗.
- 这些目标包括双重特异性氨酸-酸化调节激酶1B,黑色素瘤1炎症体的缺失,富含白的重复激酶2和分化集群147.
- 这些新兴目标为开发特定疾病的治疗方法提供了潜力.
结论:
- 对于高性心肌病 (HCM) 的新型,疾病特异性治疗方法有显著的未满足需求.
- 新兴的治疗点为HCM的未来药物开发提供了有希望的途径.
- 对这些新目标进行进一步的临床研究是有必要的,以改善患者的治疗结果.
相关概念视频
Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Cardiomyopathy V: Interprofessional Care
14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Cardiomyopathy IV: Restrictive Cardiomyopathy
12
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12
Myocarditis III: Medical Management
7
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
7


